BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Ubago, R. [1 ]
Castillo, M. A. [1 ]
Flores, S. [2 ]
Beltran, C. [1 ]
机构：
[1] Agencia Evaluac Tecnol Sanitarias Andalucia, Seville, Andalucia, Spain
[2] Andalusian Agcy Hlth & Technol Assessment, Seville, Andalucia, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A435 / A435
页数：1
相关论文
共 50 条
  • [21] Combination of cetuximab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.
    Salek, T.
    Sebo, E.
    Mazalova, D.
    Chovanec, J.
    Stresko, M.
    Thomkova, A.
    Andrasina, I.
    Barilla, R.
    Hlavata, Z.
    Mego, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [22] TITULO: RESULTS OF BEVACIZUMAB IN COMBINATION WITH FIRST LINE AND SECOND LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER
    Castano, A.
    Aristizabal, N.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 78 - 78
  • [23] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    [J]. CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [24] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    [J]. British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [25] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    [J]. ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [26] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [27] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [28] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    [J]. JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [29] A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
    Temraz, Sally
    Nasr, Fadi
    Kattan, Joseph
    Abigerges, Dany
    Moukadem, Walid
    Farhat, Fadi
    Maatouk, Layal
    Chahine, Georges
    Shamseddine, Ali
    [J]. BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 7 - 15
  • [30] Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.
    Murai, Katsuyuki
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Sugiyama, Keiji
    Tsushima, Takahiro
    Mitani, Seiichiro
    Todaka, Akiko
    Honda, Kazunori
    Yokota, Tomoya
    Narita, Yukiya
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345